515 related articles for article (PubMed ID: 33317571)
1. New agents and regimens for diffuse large B cell lymphoma.
Wang L; Li LR; Young KH
J Hematol Oncol; 2020 Dec; 13(1):175. PubMed ID: 33317571
[TBL] [Abstract][Full Text] [Related]
2. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.
Roschewski M; Phelan JD; Wilson WH
Cancer J; 2020; 26(3):195-205. PubMed ID: 32496453
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
7. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
Yamaguchi M
Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
Gordon MJ; Sureda A; Westin JR
Leuk Lymphoma; 2022 Sep; 63(9):2041-2051. PubMed ID: 35549635
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma: new targets and novel therapies.
Cheson BD; Nowakowski G; Salles G
Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic developments and advances in B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Coiffier B; Sarkozy C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):366-378. PubMed ID: 27913503
[TBL] [Abstract][Full Text] [Related]
15. New developments in the management of diffuse large B-cell lymphoma.
Habermann TM
Hematology; 2012 Apr; 17 Suppl 1():S93-7. PubMed ID: 22507791
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
Zhao T; Ren H; Wang X; Liu P; Yan F; Jiang W; Li Y; Li J; Gribben JG; Jia L; Hao J
Oncotarget; 2015 Sep; 6(29):27816-31. PubMed ID: 26315113
[TBL] [Abstract][Full Text] [Related]
17. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F
Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370
[TBL] [Abstract][Full Text] [Related]
18. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
20. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]